Latest Conference Articles

Social media can leverage pharmacists as personalities and help influence which topics the public discusses and the data they consume, presenter says.

Anthony Pudlo, PharmD, MBA, executive director of the Tennessee Pharmacists Association, discussed his presentation at the National Association of Chain Drug Stores (NACDS) 2023 Regional Chain conference.

Pudlo’s presentation focused on key shifts in chain pharmacies, including pharmacy benefit manager (PBM) reform, pharmacist-administered vaccine trends, and provider status.

Comprehensive medication management is 1 way to optimize therapy, according to Steven Chen, PharmD, FASHP, FCSHP, FNAP, who spoke at the NACDS Regional 2023 Meeting.

National Association of Chain Drug Stores CEO and president, and 2 other experts discuss the importance of advocacy on the statewide policy level.

With the growing importance of pharmacy services, Chen said pharmacists should think outside the box and get creative when finding effective payment models.

Jim Whitman, senior vice president of member programs and services at the National Association of Chain Drug Stores (NACDS), discussed the upcoming NACDS 2023 Regional Conference and what attendees can look forward to.

Zolbetuximab treatment reduced risk of death by 25% compared to placebo.

Michael Brown, vice president of Managed Services at Cardinal Health, discusses ways for pharmacists to help manage costs post-pandemic.

Jawad Saleh, PharmD, BSPharm, BCCCP, BCPS, clinical manager of Pharmacy Services at the Hospital for Special Surgery, discusses how pharmacists can treat postoperative nausea and vomiting.

In addition to ongoing staffing patterns and new technology, an expert said pharmacies will have to adapt to new ways of educating students and staff.

Clinical oncology pharmacist Amy Indorf, PharmD, BCOP, discusses her presentation on the role of PARP inhibitors for ovarian cancer.

Although progress has been made in pre-exposure prophylaxis use, there are still significant barriers for many patients.

Expert discusses the patient-reported outcomes from the GRIFFIN trial at the final study analysis after all patients completed 1 year of follow-up post maintenance therapy.

Expert discusses updated cohort of patients with longer-term follow up treated in the phase 2 clinical trial of venetoclax added to cladribine plus low-dose araC alternating with azacytidine.

Expert discusses the updated data for a trial cohort after a median follow-up of 27 months.

Richard T. Maziarz, MD, and a team of investigators assessed average medical costs of allo-HCT throughout a patient’s lifetime and the net monetary savings and value associated with reducing complications.

The FDA clinical reviewer responsible for the approval of this combination therapy discusses the data that led to the approval in May 2022.

Phase 1 clinical trial data show the drug to be active with evidence of clinically meaningful responses and a manageable safety profile.

Based on real-world outcomes, there is an unmet need for an effective therapy to be used among patients aged 75 years or older with relapsed/refractory diffuse large B-cell lymphoma.

Long-term data showed no difference in the clinical benefit between the treatments for HER2-negative early breast cancer with homologous recombination deficiency.

Although patients with Richter syndrome often experience poor outcomes, there are many new treatment strategies that have demonstrated a durable response.

Expert discusses the effect of baseline transfusion burden and luspatercept dose level on response to treatment in patients with LR-MDS from the MEDALIST study.

Expert discusses the results of a trial assessing immune reconstitution in adult patients who received Orca-T, consisting of hematopoietic stem/progenitor cells, regulatory T cells, and conventional T cells.

Expert discusses clinical outcomes of the phase 3 ZUMA-7 trial assessing axicabtagene ciloleucel versus standard-of-care in second-line large B-cell lymphoma by metabolic tumor volume.

Expert discusses the safety and efficacy of polatuzumab vedotin combined with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) as second-line treatment in a multicenter phase 2 study.

Expert discusses analysis of phase 3 MEDALIST trial data aimed to assess the probability of greater overall survival and progression-free survival benefit from luspatercept vs placebo.

Low socioeconomic status was associated with greater in-hospital mortality and decreased use of advanced therapeutic options.